BioRem Inc.
3.67CAD
-0.0400 (-1.08%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BRM.V.
Revenue
| (CAD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 28.9M | 25.2M | 37.4M | 42.4M | 52.1M | 58.9M |
| Q1 | — | — | — | — | 6.8M | — |
| Q2 | — | — | — | 9.4M | 15.7M | — |
| Q3 | — | — | — | 11.3M | — | — |
| Q4 | — | — | — | 16.9M | — | — |
Revenue
| (CAD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .090 | .130 | .160 | .260 | .340 | .430 |
| Q1 | — | — | — | .002 | .011 | — |
| Q2 | — | — | — | .040 | .105 | — |
| Q3 | — | — | — | .062 | — | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| .156 |
| — |
| — |
Debt level and coverage